摘要
Abstract
Objective To investigate the clinical efficacy of Flupentixol and Melitracen combined with Fluoxetine in the treatment of depression after cerebral infarction.Methods 78 cases of depression after cerebral infarction in our hospital from April 2012 to April 2014 were randomly divided into observation group (n=40) and control group (n=38).Control group was treated with Fluoxetine,and observation group was treated with Flupentixol and Melitracen on the basis of control group.Analyzed the clinical effect,HAMD score and NIHSS score in both groups.Results After treatment,the total efficiency of observation group was 92.50％,and that of control group was 73.68％,with statistically significant difference (x 2=4.967,P＜0.05).There were no statistically significant differences in HAMD score and NIHSS score between two groups before treatment (P＞0.05);HAMD score and NIHSS score in both two groups significantly decreased after treatment (P＜0.05),HAMD score and NIHSS score in observation group after treatment were significantly lower than those in control group (P＜0.05).The incidence of adverse events was 27.50％ in observation group,23.68％ in control group,without statistically significant difference between two groups (x 2=0.101,P＞0.05).Conclusion The clinical efficacy of Flupentixol and Melitracen combined with Fluoxetine in the treatment of depression after cerebral infarction is significant,which is helpful to the recovery of depression symptoms and neurological function compared with treatment with Fluoxetine alone,worthy of clinical promotion.关键词
黛力新/氟西汀/脑梗死后抑郁/疗效Key words
Flupentixol and Melitracen/Fluoxetine/Depression after cerebral infarction/Efficacy
